Market Size of Europe Alpha-Glucosidase Inhibitors Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 2.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Alpha-Glucosidase Inhibitors Market Analysis
The Europe Alpha-Glucosidase Inhibitors Market size is expected to reach USD 1 billion over the forecast year, growing at a CAGR of 2.20% during the forecast period.
The COVID-19 epidemic has had a significant effect on the market for insulin drugs and devices. Patients with type-1 diabetes are more affected by COVID-19. Since people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the manufacturers of insulin drugs worked with local governments to provide insulin drugs to diabetes patients.
NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin drugs.
The rates of newly diagnosed Type 1 and Type 2 diabetes cases are seen increasing among the youth in Europe. The prevalence of diabetes among all ages in the European region is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The prevalence of autoimmune Type 1 diabetes is also increasing in Europe, and as per sources, Europe has the highest number of children with Type 1 diabetes. Though Type 2 patients are initiated with oral drugs, insulin may also be required when glucose levels are not well controlled due to an unhealthy lifestyle. Thus, the demand for insulin also exists among Type 2 diabetes patients.
The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Europe are indications of the increasing usage of diabetic drug products. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Europe Alpha-Glucosidase Inhibitors Industry Segmentation
Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. By competitive inhibition, they block enzymes that convert complicated non-absorbable carbs into simple, absorbable carbohydrates. Glucoamylase, sucrase, maltase, and isomaltase are some of these enzymes. Europe Alpha-Glucosidase Inhibitors Market is segmented by geography (Germany, Spain, Italy, France, United Kingdom, Russia, and the rest of Europe). The report offers the value (in USD) and Volume (in units) for the above segments.
| Drug | |
| Alpha-glucosidase Inhibitors |
| Geography | |
| Germany | |
| Spain | |
| Italy | |
| France | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Europe Alpha-Glucosidase Inhibitors Market Size Summary
The Europe Alpha-Glucosidase Inhibitors Market is poised for growth, driven by the increasing prevalence of diabetes across the region. The rise in diabetes cases, particularly among the youth, is attributed to factors such as obesity, unhealthy diets, and physical inactivity. This surge in diabetes prevalence has led to a corresponding increase in healthcare expenditure, as European nations grapple with the financial burden of managing this chronic condition. The market is characterized by the presence of key players like Bayer, SunPharma, Pfizer, and Takeda, who are actively involved in the development and distribution of diabetes medications. Technological advancements in diabetes care, such as Medtronic's integrated smart insulin pen, are also contributing to the market's expansion by offering more precise insulin delivery solutions.
Alpha-glucosidase inhibitors, including acarbose, miglitol, and voglibose, are being studied for their potential role in managing diabetes, particularly in patients with high postprandial glucose levels. While these inhibitors are not considered first-line therapy due to their limited efficacy and gastrointestinal side effects, they may be beneficial as part of a combination regimen for individuals with high-carbohydrate diets. The market's growth is further supported by ongoing research and drug repurposing efforts, as well as regulatory actions such as price fixing by the Indian Drug Pricing Authority. Despite the challenges, the market is expected to continue its upward trajectory, driven by the increasing incidence of obesity and genetic risk factors for type-2 diabetes.
Europe Alpha-Glucosidase Inhibitors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Drivers
-
1.3 Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. Market Segmentation
-
2.1 Drug
-
2.1.1 Alpha-glucosidase Inhibitors
-
-
2.2 Geography
-
2.2.1 Germany
-
2.2.2 Spain
-
2.2.3 Italy
-
2.2.4 France
-
2.2.5 United Kingdom
-
2.2.6 Russia
-
2.2.7 Rest of Europe
-
-
Europe Alpha-Glucosidase Inhibitors Market Size FAQs
What is the current Europe Alpha-Glucosidase Inhibitors Market size?
The Europe Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 2.20% during the forecast period (2024-2029)
Who are the key players in Europe Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Europe Alpha-Glucosidase Inhibitors Market.
